Efficacy and Safety of CD5024 1% in Acne Vulgaris

Summary

Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.

Timeline

Start

2016-04-25

Primary completion

2016-11-02

Completion

2016-11-02

Outcome

Missed primary endpoint

registry analysis (superiority test); CD5024 1% Cream vs CD5024 1% Cream Matched Placebo; p = 0.158; Wilcoxon rank signed test NCT03034460 ↗

Drugs

Indications